Merck & Co., Inc. outside the United States and Canada, is one of the largest pharmaceutical companies in the world. The Merck headquarters is located in Whitehouse Station, New Jersey, an unincorporated area in Readington Township.
The company was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co. was confiscated in 1917 during World War I and then set up as an independent company. Currently, it is one of the seven largest pharmaceutical companies in the world both by market capitalization and revenue.
Merck & Co. or MSD describes itself as a "a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures." The Merck Company Foundation has distributed over $480 million to educational and non-profit organizations since it was founded in 1957. Merck publishes
The Merck Manuals, a series of medical reference books. These include the Merck Manual of Diagnosis and Therapy, the world's best-selling medical textbook, and the Merck Index, a collection of information about chemical compounds.
Role of Merck in different fields
Research and Development
Our 2,500 professionals around the world in Research and Development apply their combined knowledge, creativity and passion every day to push forward into new frontiers of medical science.
In Research, we employ state-of-the-art technology in searching for breakthrough therapeutic solutions, including exciting new possibilities opened up by human genomics. Scientific rigor, laboratory experience and even human intuition are critical to selecting the best drug candidates.
Our Clinical Development organization transforms biologically active compounds and new chemical entities into safe, effective medicines of the highest quality. Managing dozens of simultaneous trials with thousands of patients around the world is a monumental task that demands strategic planning as well as attention to the smallest details.
Above all, it requires an absolute dedication to safeguarding the health of patients.
At every link in the chain from initial discovery to rigorous pre-clinical testing and clinical development, we examine the value of integrating the expertise of external partners to move our projects forward. Throughout our R&D organization, there is a real sense of urgency to discover and develop better medical treatments that will transform the lives of patients afflicted by cancer, multiple sclerosis, infertility or other serious diseases.
Merck scientists discover and develop medicines that have the potential to help save or improve countless lives around the world. An important part of our strategy for leadership in science and technology is finding the best, most varied talent. Then, we provide a work environment that helps them achieve and encourages them to stay. We recruit researchers who are leaders in their scientific and technical disciplines – people with the enthusiasm and drive to help provide medicines that save lives and improve the quality of life for our patients.
Behind each of our medicines and vaccines is a team of researchers who are leaders in their fields. People whose unwavering enthusiasm for finding new ways to prevent and treat disease is matched only by their unrelenting commitment to scientific excellence and patient safety.
MRL comprises eight functional areas. Each area provides expert, efficient support of our drug candidates – ushering them from drug discovery and preclinical studies to late stage clinical development.
- Discovery and Preclinical Sciences
- Global Clinical Development and Regulatory Affairs
- Global Scientific Strategy
- Project and Pipeline Management
- Biologics Research
- Vaccine Research
- Emerging Markets R&D
- Worldwide Licensing and Knowledge Management
We are entering an exciting period with a strong product pipeline that targets a broad range of diseases. And we're looking ahead to the next generation of healthcare by using new techniques and technologies.
We focus our research on several key therapeutic areas, including:
- Diabetes and Obesity
- Bone, Respiratory, Immunology, and Dermatology
- Infectious Disease
- Neurosciences and Ophthalmology
- Women's Health and Endocrine
In the Pipeline
From preclinical development to Phase III clinical trials, our passion for advancing health through science is evident in the breadth and depth of our pipeline.
Merck's Fight Against HIV/AIDS
We've now entered the fourth decade of the AIDS epidemic, and according to The Joint United Nations Commission on HIV/AIDS (UNAIDS), the world has turned the corner. Since the epidemic peaked in 1999, the number of new infections has fallen by 19 percent. And, of the estimated 15 million people living with HIV in low- and middle income countries, 6.6 million have access to treatment.
Despite the positive trend overall, there is more work to be done. For example, while the rate of new HIV infections has declined globally, in some countries in Eastern Europe and Central Asia there are signs that new HIV infections are on the rise.
For nearly 25 years, Merck has sought to make a difference in the fight against HIV/AIDS through research, access programs and global partnerships. We are committed to the long-term battle against this disease.
Our commitment means that we are applying our scientific, operational and technological expertise to deliver healthcare solutions to help the millions of people worldwide who are living with HIV/AIDS.
As part of Merck's commitment to Corporate Responsibility, we support a variety of programs around the world.
Products on the market
· Antivenin – for the treatment of black widow spider (Latrodectus mactans) bites
· Fosamax (alendronate) – osteoporosis medication.
· Hyzaar (losartan/hydrochlorothiazide) – used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.
· Isentress (raltegravir) – HIV integrase inhibitor.
· Trusopt (dorzolamide) – reduces intraocular pressure in people with glaucoma or ocular hypertension.
· Zetia (ezetimibe) – cholesterol absorption inhibitor which lowers LDL co marketed by Schering-Plough
Products under development
- An antidote for statin toxicity involving CoQ10 (which has been held for over 20 years without producing it)
Our Information Technology (IT) professionals are innovative thinkers with strong leadership skills. They provide technical solutions that enhance the way we do business. These solutions allow us to work faster – and smarter – around the world.
Whether engaged in network engineering, business analysis, data modeling or applications architecture, our IT people provide solutions to maximize the company’s overall performance.
Information Technology opportunities exist in many areas at Merck.
- We look for a balance of strong technical competency and business acumen. For many of our positions, we look for Sigma certifications, project management certifications and/or technical certifications.
- We recruit individuals with experience in the following: Account Management, Business Architecture, Business Analysis, Program Management, Business Management, Solution Partnering, Solution Management, Delivery Support/Service, Technical Analysis, Program Development and Program Engineering.
Merck’s communications professionals are the voice of the company. They aim to differentiate Merck based on the strengths of our products, pipeline, performance and people. They do this by communicating with and to a diverse group: the media, the financial community, customers, stockholders,employees, policymakers and governments.
Merck offers a variety of positions in the communications field.
We recruit individuals with backgrounds in Communications, Liberal Arts, Business and Journalism.
for further,click here
for further,click here